Recommendation based on FLAURA2 results which showed Tagrisso plus chemotherapy extended median progression-free survival by nearly 9 months
Data support the potential of Dupixent as the first new treatment approach in more than a decade and first-ever targeted therapy for COPD
Additional data from APPRAISE ATP trial reinforce modular therapy approach
Recommendation based on CAPItello-291 results which showed the Truqap combination reduced the risk of disease progression or death by 50%
First and only AKT inhibitor approved in Japan for breast cancer patients with specific biomarker alterations
The U.S. FDA recently approved Xolair as the first and only medicine for children and adults with one or more food allergies
First-in-class AKT inhibitor has potential to reshape treatment for breast cancer patients
XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy in nonmetastatic castration-sensitive prostate cancer
Approval based on results from TOPAZ-1 global Phase III trial and a Chinese patient
In the Phase 3 LIBRETTO-431 study, Retevmo more than doubled progression-free survival (PFS) compared to chemotherapy plus pembrolizumab in patients with advanced or metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC)
Subscribe To Our Newsletter & Stay Updated
